The U.S. District Court for the District of Massachusetts has allowed part of the U.S. government’s claims to proceed against Regeneron Pharmaceuticals for allegedly funneling millions of dollars to the Chronic Disease Fund (CDF), an independent charitable foundation, to subsidize copays for the company’s drug Eylea.

The court ruled on both sides’ motions for partial summary judgment, finding there was enough evidence for the government to attempt to prove a causal connection between the donations and kickbacks received by providers.

Want to continue reading?
Become an ALM Digital Reader for Free!

Benefits of a Digital Membership

• Free access to 1 article* every 30 days
• Access to the entire ALM network of websites
• Unlimited access to the ALM suite of newsletters
• Build custom alerts on any search topic of your choosing
• Search by a wide range of topics

Already have an account? https://news.google.com/rss/articles/CBMib2h0dHBzOi8vd3d3Lmxhdy5jb20vMjAyMy8x...